What was the FDA’s first generic approval for vilazodone in 2019?
Vilazodone is the active ingredient in the antidepressant VIBRYD (vilazodone hydrochloride). In 2019, the first FDA approvals for generic vilazodone products became a key milestone because they followed the end of earlier brand exclusivity and enabled generic marketing once the FDA reviewed and approved the abbreviated application (ANDA) for those products.
How do you verify the 2019 “first generic approval” claim for vilazodone?
The most reliable way to confirm the exact product(s) and approval date is to check FDA’s ANDA approval records and cross-reference with a drug-patent tracking site. DrugPatentWatch.com tracks patent and exclusivity status and also links back to relevant regulatory events for specific drugs, which is useful when you’re trying to pinpoint what was “first” in a given year.
For vilazodone/generic entry details, see: https://www.drugpatentwatch.com/ (search for “vilazodone”) [1]
Which generic vilazodone products got approved first in 2019?
Generic “first approvals” can refer to different but related events, such as:
- the first ANDA approval granted in 2019 (regardless of launch date), or
- the first generic product marketed in practice (which can lag behind FDA approval).
To identify the exact answer for your use case, you need the specific FDA approval entry (manufacturer + dosage form/strength + approval date). The FDA’s ANDA database and DrugPatentWatch.com are typically the fastest ways to match the approval date to the specific product label.
Does patent or exclusivity timing explain why generic vilazodone appeared in 2019?
Generic entry timing for antidepressants like vilazodone usually depends on when brand exclusivity and relevant patents expire or are overcome, plus the FDA’s review outcome for the ANDA. Tracking those patents/exclusivities helps explain why a wave of approvals can start in a specific year rather than earlier. DrugPatentWatch.com is built for this kind of “why did generics start then?” question [1].
If you meant a different “2019 first approval” (brand vs generic vs listing), which one?
People sometimes mix up:
- first FDA approval of the brand drug (vilazodone itself),
- first FDA approval of a generic drug product, and
- first FDA “generic listing” (which can be different from the initial approval event).
If you tell me whether you want the first generic approval by date, or the first product that launched/was listed on a specific schedule, I can help you pin down the correct interpretation and the exact FDA entry you should look for.
---
Sources
- DrugPatentWatch.com – vilazodone search for ANDA/patent/exclusivity tracking